AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES...

Area of Science:

• Endocrinology and Bone Metabolism
• Clinical Diagnostics and Therapeutics

Background:

• Osteoporosis is a significant public health concern characterized by low bone mineral density (BMD) and increased fracture risk.
• Bone turnover markers (BTMs) reflect bone formation and resorption rates, offering insights into skeletal dynamics.
• Current guidelines recommend BTMs for monitoring osteoporosis treatment efficacy and assessing fracture risk.

Purpose of the Study:

• To provide an evidence-based overview of the clinical utility of BTMs in managing osteoporosis.
• To summarize current recommendations for BTM use in assessing treatment response and predicting fracture risk.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) and observational studies evaluating BTMs in osteoporosis.
• Analysis of data from major osteoporosis research consortia and clinical trials.
• Assessment of BTMs including serum carboxy-terminal propeptide of type I collagen (PINP) and serum C-terminal telopeptide (S-CTX).

Main Results:

• BTMs demonstrate significant correlations with BMD changes and fracture incidence in response to osteoporosis therapies.
• Specific BTMs, such as PINP and S-CTX, show promise in predicting treatment response and fracture risk.
• Serial BTM measurements can help identify patients who are not responding adequately to therapy.

Conclusions:

• BTMs are valuable tools for personalized osteoporosis management, complementing BMD measurements.
• Routine monitoring of BTMs can optimize therapeutic strategies and improve patient outcomes in osteoporosis.
• Further research is warranted to standardize BTM assays and establish universal reference ranges.